Celltrion Receives Health Canada’s Approval for Remsima SC (biosimilar, infliximab) for Rheumatoid Arthritis

February 2, 2021 Auto Bot Biosimilars, Canada, Health, Marketing Authorization, People, receives, rheumatoid arthritis, Treatment 0

Shots:

  • The Health Canada has granted a NOC which is based on clinical evidence for Remsima/CT-P13 SC vs CT-P13 IV up to 1year in patients with RA. The results demonstrated that switching patients from Remsima IV to its SC formulation @30wks. is comparable to maintaining Remsima SC up to 54wks.
  • The therapy has shown similar efficacy and safety profile of CT-P13 IV and provides patients an opportunity of self-administration to control their own treatment
  • The company applied patent protection until 2038 for Remsima SC in ~ 100 countries throughout North America, EU and Asia and will be the first product to enter the Canadian market

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: CBIZ

The post Celltrion Receives Health Canada’s Approval for Remsima SC (biosimilar, infliximab) for Rheumatoid Arthritis first appeared on PharmaShots.